References
1. Maitland-van der Zee, A.H., A. de Boer, and H.G. Leufkens, The
interface between pharmacoepidemiology and pharmacogenetics. Eur J
Pharmacol, 2000. 410 (2-3): p. 121-130.
2. Abrahams, E., Right drug-right patient-right time: personalized
medicine coalition. Clin Transl Sci, 2008. 1 (1): p. 11-2.
3. Lazarou, J., B.H. Pomeranz, and P.N. Corey, Incidence of
adverse drug reactions in hospitalized patients: a meta-analysis of
prospective studies. JAMA, 1998. 279 (15): p. 1200-5.
4. Evans, W.E. and H.L. McLeod, Pharmacogenomics–drug
disposition, drug targets, and side effects. N Engl J Med, 2003.348 (6): p. 538-49.
5. Prado, M.S., K. Bendtzen, and L.E.C. Andrade, Biological
anti-TNF drugs: immunogenicity underlying treatment failure and adverse
events. Expert Opin Drug Metab Toxicol, 2017. 13 (9): p.
985-995.
6. Gomez, A. and M. Ingelman-Sundberg, Pharmacoepigenetics: its
role in interindividual differences in drug response. Clin Pharmacol
Ther, 2009. 85 (4): p. 426-30.
7. Choi, J.R., et al., Genetic Variations of Drug Transporters Can
Influence on Drug Response in Patients Treated with Docetaxel
Chemotherapy. Cancer Res Treat, 2015. 47 (3): p. 509-17.
8. Hoehndorf, R., M. Dumontier, and G.V. Gkoutos, Identifying
aberrant pathways through integrated analysis of knowledge in
pharmacogenomics. Bioinformatics, 2012. 28 (16): p. 2169-75.
9. Tozzi, V., R. Libertone, and G. Liuzzi, HIV pharmacogenetics in
clinical practice: recent achievements and future challenges. Curr HIV
Res, 2008. 6 (6): p. 544-54.
10. Harper, A.R. and E.J. Topol, Pharmacogenomics in clinical
practice and drug development. Nat Biotechnol, 2012. 30 (11):
p. 1117-24.
11. Phillips, K.A., et al., Potential role of pharmacogenomics in
reducing adverse drug reactions: a systematic review. JAMA, 2001.286 (18): p. 2270-9.
12. Pouget, J.G., et al., Pharmacogenetics and outcome with
antipsychotic drugs. Dialogues Clin Neurosci, 2014. 16 (4): p.
555-66.
13. Flowers, C.R. and D. Veenstra, The role of cost-effectiveness
analysis in the era of pharmacogenomics. Pharmacoeconomics, 2004.22 (8): p. 481-93.
14. Savage, D.R., U.S. Food, and A. Drug, FDA guidance on
pharmacogenomics data submission. Nat Rev Drug Discov, 2003.2 (12): p. 937-8.
15. Davies, S.M., Pharmacogenetics, pharmacogenomics and
personalized medicine: are we there yet? ASH Education Program Book,
2006. 2006 (1): p. 111-117.
16. Leong, S.L., et al., Roles of pharmacogenomics in
non-anthracycline antineoplastic-induced cardiovascular toxicities: A
systematic review and meta-analysis of genotypes effect. International
journal of cardiology, 2019. 280 : p. 190-197.
17. Lowitt, M.H. and N.H. Shear, Pharmacogenomics and
dermatological therapeutics. Archives of dermatology, 2001.137 (11): p. 1512-1514.
18. Cavallari, L.H., J. Shin, and M.A. Perera, Role of
pharmacogenomics in the management of traditional and novel oral
anticoagulants. Pharmacotherapy: The Journal of Human Pharmacology and
Drug Therapy, 2011. 31 (12): p. 1192-1207.
19. Lunshof, J.E. and D. Gurwitz, Pharmacogenomic testing: knowing
more, doing better. Clin Pharmacol Ther, 2012. 91 (3): p.
387-9.
20. Wadelius, M. and A. Alfirevic, Pharmacogenomics and
personalized medicine: the plunge into next-generation sequencing .
2011, Springer.
21. Shah, J., Criteria influencing the clinical uptake of
pharmacogenomic strategies. BMJ, 2004. 328 (7454): p. 1482-6.
22. Overby, C.L., et al., Feasibility of incorporating genomic
knowledge into electronic medical records for pharmacogenomic clinical
decision support. BMC Bioinformatics, 2010. 11 Suppl 9 : p.
S10.
23. Altar, C.A., et al., Clinical validity: Combinatorial
pharmacogenomics predicts antidepressant responses and healthcare
utilizations better than single gene phenotypes. Pharmacogenomics J,
2015. 15 (5): p. 443-51.
24. Benitez, J., et al., The clinical validity and utility of
combinatorial pharmacogenomics: Enhancing patient outcomes. Appl Transl
Genom, 2015. 5 : p. 47-9.
25. Carlberg, C., The need for education in personalized
medicine. Personalized medicine, 2012. 9 (2): p. 147-150.
26. Zachary III, W. and E.P. Armstrong, Health care professionals’
perceptions of the role of pharmacogenomic data. Journal of Managed
Care Pharmacy, 2002. 8 (4): p. 278-284.
27. Tranter, B. and S. Noble, Communication in oncology pharmacy:
The challenge of treatment adherence. Oxford Textbook of Communication
in Oncology and Palliative Care, 2017: p. 328.
28. K Zgheib, N., F. Ghaddar, and R. Sabra, Teaching
pharmacogenetics in low and middle-income countries: team based learning
and lessons learned at the American University of Beirut. Current
Pharmacogenomics and Personalized Medicine (Formerly Current
Pharmacogenomics), 2011. 9 (1): p. 25-40.
29. Elewa, H., et al., A survey on the awareness and attitude of
pharmacists and doctors towards the application of pharmacogenomics and
its challenges in Qatar. J Eval Clin Pract, 2015. 21 (4): p.
703-9.
30. AlEjielat, R., et al., An evaluation of the knowledge,
opinions, expectations and concerns toward pharmacogenomics among
Jordanian pharmacists. Personalized medicine, 2016. 13 (2): p.
143-154.
31. Muzoriana, N., et al., Knowledge, attitude, and perceptions of
pharmacists and pharmacy students towards pharmacogenomics in Zimbabwe.Pharmacy, 2017. 5 (3): p. 36.
32. Perwitasari, D., et al., Knowledge, Awareness and Attitude of
Pharmacists toward Pharmacogenetic Practice: Perspective of Community
and Hospital in Yogyakarta, Indonesia. J Community Med Health Educ,
2017. 7 (568): p. 2161-0711.1000568.
33. Abdela, O.A., et al., Ethiopian health care professionals’
knowledge, attitude, and interests toward pharmacogenomics.Pharmacogenomics and personalized medicine, 2017. 10 : p. 279.
34. Albassam, A., et al., Knowledge, perceptions and confidence of
physicians and pharmacists towards pharmacogenetics practice in Kuwait.PloS one, 2018. 13 (9).
35. Offit, K., Personalized medicine: new genomics, old lessons.Human genetics, 2011. 130 (1): p. 3-14.
36. Xie, B., D.M. Dilts, and M. Shor, The physician–patient
relationship: the impact of patient‐obtained medical information.Health economics, 2006. 15 (8): p. 813-833.
37. Arathy, R., J. Chacko, and S. Pillai, A knowledge, attitude,
and practices study of pharmacogenomics and its educational needs among
doctors in a tertiary care hospital. National Journal of Physiology,
Pharmacy and Pharmacology, 2019. 9 (2): p. 99-102.
38. Collins, F.S., M. Morgan, and A. Patrinos, The Human Genome
Project: lessons from large-scale biology. Science, 2003.300 (5617): p. 286-90.
39. Jarrar, Y., Perception of primary care physicians’ toward
pharmacogenetics in Jordan. Jordan Med J, 2019. 53 (3): p.
81-89.
40. Gallipani, A., et al., Prescriber Attitudes Toward
Implementation of Pharmacogenomic Testing in a Family Medicine Residency
Program. PRiMER, 2018. 2 .
41. Bonter, K., et al., Personalised medicine in Canada: a survey
of adoption and practice in oncology, cardiology and family medicine.BMJ open, 2011. 1 (1): p. e000110.
42. Hui, C.H. and H.C. Triandis, Effects of culture and response
format on extreme response style. Journal of Cross-Cultural Psychology,
1989.
43. NO, T.D.H., Arab Cultural Awareness: 58 Factsheets. 2006.